The GSK3A Knockout 769-P Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of 769-P cells with targeted disruption of the GSK3A gene. As a heterogeneous pool, this knockout model captures a range of editing outcomes, offering a robust system for functional genomics studies without the limitations of clonal expansion. The polyclonal format is ideal for pooled screens, pathway analyses, and high-throughput applications where population-level effects are of primary interest.
The human 769-P cell line is a renal cell carcinoma line established from a primary clear cell adenocarcinoma. Notably, these cells express wild-type VHL, distinguishing them from many ccRCC models and enabling the study of VHL-independent oncogenic pathways. Their epithelial morphology and well-documented signaling responses render them a reliable substrate for genetic manipulation and phenotypic analysis in renal cancer research. This model is widely utilized to dissect signaling networks that drive renal tumor cell proliferation and survival.
GSK3A is a serine/threonine kinase that negatively regulates canonical Wnt/??-catenin signaling. In the destruction complex with AXIN and APC, GSK3A phosphorylates ??-catenin, targeting it for degradation. WNT3A binding to Frizzled/LRP5/6 activates DVL, inhibiting GSK3A and allowing ??-catenin to accumulate and activate TCF/LEF-dependent transcription of c-MYC and Cyclin D1. GSK3A is also regulated by AKT-mediated phosphorylation downstream of insulin/PI3K and by p53, IL-6, and EGF, with interactions with FRAT1 and PP2A fine-tuning its activity.
In 769-P ccRCC cells with wild-type VHL, GSK3A knockout facilitates targeted exploration of Wnt/??-catenin-driven oncogenesis independent of hypoxia pathway alteration. This model enables assessment of how disrupted GSK3A function impacts ??-catenin accumulation, cell proliferation, and survival, and serves as a valuable tool for evaluating therapeutic GSK3 inhibition strategies and identifying synthetic lethal relationships in renal cell carcinoma. Moreover, the polyclonal nature of the knockout population better mimics tumor heterogeneity, providing insights into population-level responses to genetic perturbation.
This polyclonal knockout product supports applications such as GSK3 inhibitor target validation, mechanistic studies of Wnt signaling in cancer, and investigation of insulin and PI3K/AKT pathway cross-talk. Compatible experimental techniques include Western blotting for ??-catenin and phospho-GSK3A, TOP/FOP flash reporter assays, qRT-PCR for Wnt target genes, immunofluorescence for ??-catenin localization, and cell proliferation or apoptosis assays. Researchers can employ this model in high-content screening, pathway analysis, and drug discovery programs focused on renal cell carcinoma and other GSK3A-related diseases. For additional information, please contact Ascent Research.
